TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04978324

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: leukocyte platelet rich fibrin (L-PRF)
Description: Participants blood will be spun to obtain L-PRF strips and liquid L-PRF. Pockets will receive insertion of small L-PRF strips followed by liquid L-PRF injections to fill the 5-8mm pockets of the test side.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: leukocyte platelet rich fibrin (L-PRF)
Description: Participants blood will be spun to obtain L-PRF strips and liquid L-PRF. Pockets will receive insertion of small L-PRF strips followed by liquid L-PRF injections to fill the 5-8mm pockets of the test side.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and Root Planing
Description: Scaling and root planing, which is the standard of care, will be performed on the control side using Cavitron and hand scalers on test and control sides under local anesthesia.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and Root Planing
Description: Scaling and root planing, which is the standard of care, will be performed on the control side using Cavitron and hand scalers on test and control sides under local anesthesia.
Study: NCT05543538

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multimedia audio-visual program
Description: Participants in the control group will receive teaching method with multimedia audio-visual material.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multimedia audio-visual program
Description: Participants in the control group will receive teaching method with multimedia audio-visual material.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: multimedia audio-visual program
Description: Participants in the control group will receive teaching method with multimedia audio-visual material.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experiential learning programmes
Description: Participants in the experimental group will receive teaching method with experiential learning.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experiential learning programmes
Description: Participants in the experimental group will receive teaching method with experiential learning.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: teachers' personal demonstration
Description: Participants in the experience group will receive teachers' personal demonstration.
Study: NCT05983796

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-HER2 PET
Description: 18F-HER2 PET
Study: NCT05922644

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCS
Description: 21 days of cervical spinal cord electrical stimulation treatment in addition to routine brain resuscitation and rehabilitation awakening treatment.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conventional
Description: Routine brain resuscitation and rehabilitation awakening treatment.
Study: NCT05270980

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cohorting
Description: The cohorting strategy will result in pairing serology-positive staff with serology-negative residents and serology-negative staff and serology-positive residents to the degree that penetration of serologic presumed immunity allows this pairing to be positive. Any resident who refuses serology testing will be treated as if they are serology negative as the safest strategy for risk of unwanted exposure.
Study: NCT05460949

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HOLD RELAX STRETCHING OF ILIOPSOAS
Description: 10 second isometric contraction of iliopsoas muscle (HR), 10-second rest, 20 second static stretch, 5 repetitions.~• The stretching exercise was performed 2 times a week for 8 weeks. 10 second isometric contraction of iliopsoas muscle (HR), 10-second rest, 20 second static stretch, 5 repetitions.~The stretching exercise was performed 2 times a week for 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WILLIAM'S PROTOCOL
Description: Pelvic tilt Single Knee to chest Double knee to chest Partial sit-up Hamstring stretch Hip Flexor stretch Squat Each group performed special trainings for 8 weeks, 2 sessions per week; each session took about 1 hour. Duration of each exercise was 8 to 10 seconds in each set. Protocols were started with 1 set of 10 repetitions at starting baseline and by improving performance and patients' compatibility with trainings, all eventually finished with 3 sets of 20 repetitions at the end of protocols.
Study: NCT04987463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vigabatrin
Description: Vigabatrin in capsules administered orally, initially (between V1 and V2) once daily in the evening,and starting from V2 administered two times daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: Rapamycin in liquid administered orally, in the morning, every other day or daily depending on the patient's body weight. The starting dose of rapamycin will be calculated according to the body weight of the patient measured at V1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo in liquid administered orally, once daily, in the morning. The starting dose of placebo in liquid will be calculated according to the body weight of the patient measured at V1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo in granules administered orally, initially once daily in the evening,and after reaching the targeted dose administered two times daily.
Study: NCT06135844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Purell Hand Sanitizer
Description: Active ingredient. Ethyl alcohol 70%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Medical Grade Mineral Oil
Description: Inert ingredients: Saturated hydrocarbons, with a purity and chemical structure that differs substantially from food-grade or technical-/industrial-grade mineral oils.
Study: NCT03870334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT-11 880 mg
Description: Oral once daily tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral once daily tablet
Study: NCT05130827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plinabulin
Description: 40mg flat dose IV infusion, infused over approximately 30 minutes starting between 1-3 hours after stem cell infusion on day 0.
Study: NCT05837273

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fully-immersive VR
Description: For fully-immersive VR sets the highest level of immersion of VR technologies, presenting improvement in cognitive function in cognitive decline seniors. Fully immersive VR-based cognitive training also has a positive effect on psychological performance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: For the cognitive training, the therapy is a non-pharmacological approach, used for a series of standardized tasks to maintain or even increase person's cognitive function. The therapy can effectively improve multiple cognitive performance, such as: attention, reaction time (processing speed), working memory, and visual-spatial ability.
Study: NCT04833777

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local Anesthetics Lidocaine
Description: 10 mL 1% lidocaine with 1:100,000 epinephrine and 1 mL 8.4% sodium bicarbonate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local Anesthetics Bupivacaine
Description: 5 mL 1% lidocaine with 1:100,000 epinephrine + 5 mL 0.5% bupivacaine with 1:100,000 epinephrine and 1 mL 8.4% sodium bicarbonate
Study: NCT04716972

Intervention type: OTHER
Intervention: survey
Description: Online survey

Intervention type: OTHER
Intervention: Interview
Description: Interview
Study: NCT05722730

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pilates Exercises
Description: The intervention group will perform an exercise protocol based on the Pilates method, by a physiotherapist specialized in Pilates and independent of the researchers, using the method's own equipment, with a frequency of 2x/week, for 12 weeks in therapeutic sessions of identical protocols lasting 60 min.
Study: NCT05504837

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KB407 (Nebulization)
Description: Nebulized solution of KB407, a replication-defective HSV-1 expressing full length human CFTR

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KB407 (Nebulization)
Description: Nebulized solution of KB407, a replication-defective HSV-1 expressing full length human CFTR

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KB407 (Nebulization)
Description: Nebulized solution of KB407, a replication-defective HSV-1 expressing full length human CFTR
Study: NCT06203509

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thrive Intervention
Description: • The THRIVE Clinical Pathway is a standardized transitional care clinical pathway that supports Medicaid insured or Medicaid eligible individuals being managed for both chronic diseases and serious mental illness following hospitalization.
Study: NCT05862493

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FOCUS echocardiography
Description: Preoperative FOCUS echocardiography. Based on FOCUS information: correction of low level of venous return and/or step-up monitoring and/or vasoactive drugs
Study: NCT05262816

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: electroacupuncture
Description: electroacupuncture at Sanyinjiao (SP6)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: electroacupuncture at Sanyinjiao (SP6)
Study: NCT05736328

Intervention type: PROCEDURE
Intervention: Traction
Description: Postoperative lower extremity traction
Study: NCT05947604

Intervention type: DRUG
Group type: OTHER
Intervention: Acoziborole
Description: Acoziborole 960 mg (three tablets of 320 mg) for oral route in fasted condition Period 2: single oral administration on Day 12

Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam
Description: • Midazolam 5 mg syrup in fasted condition Period 1: Single oral dose of 5 mg administered on Day 8 Period 2: Single oral dose of 5 mg administered on Day 21

Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam
Description: • Midazolam 5 mg syrup in fasted condition Period 1: Single oral dose of 5 mg administered on Day 8 Period 2: Single oral dose of 5 mg administered on Day 21

Intervention type: DRUG
Group type: OTHER
Intervention: Dextromethorphan
Description: • Dextromethorphan 15 mg syrup in fasted condition Period 1: Single oral dose of 15 mg administered on Day 1 Period 2: Single oral dose of 15 mg administered on Day 14

Intervention type: DRUG
Group type: OTHER
Intervention: Dextromethorphan
Description: • Dextromethorphan 15 mg syrup in fasted condition Period 1: Single oral dose of 15 mg administered on Day 1 Period 2: Single oral dose of 15 mg administered on Day 14
Study: NCT05743153

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal intervention program
Description: Exercise intervention: combined endurance and resistance training three times a week using workout video's which patients can do at home. Advice to exercise at low-intensity for at least 30 minutes per day.~Nutritional intervention: Patients are advised to aim for optimal energy and protein intake (by registered dietician) and to avoid red meat, processed foods and sweetened drinks. Aiming for a mainly plant based diet.~Psychological intervention: screening for psychological risk factors and if present, patients are referred to a psychologist for psychological support.
Study: NCT05881655

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airdoc Red Lighting Device
Description: A medical device with ultra low lever laser irradiance of 0.6mW or 1.2mW at the surface of cornea. And the therapy lasts 3 minutes with the 4 hours or more interval of break.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airdoc Red Lighting Device
Description: A medical device with ultra low lever laser irradiance of 0.6mW or 1.2mW at the surface of cornea. And the therapy lasts 3 minutes with the 4 hours or more interval of break.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Special Spectacles to Control Myopia
Description: Customer designed power and fitting to each subject for all the study periods.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Special Spectacles to Control Myopia
Description: Customer designed power and fitting to each subject for all the study periods.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Special Spectacles to Control Myopia
Description: Customer designed power and fitting to each subject for all the study periods.
Study: NCT06426667

Intervention type: PROCEDURE
Intervention: posterior tibial nerve radiofrequency
Description: pulse radiofrequency at 45 V for 300 seconds at 42 degrees Celsius is applied to the posterior tibial nerve area. During the procedure, the temperature at the electrode tip is kept below 42°C. Following negative aspiration (in the absence of blood), 2 cc of 1% lidocaine + 4 mg dexamethasone is applied to the same area.

Intervention type: PROCEDURE
Intervention: posterior tibial nerve radiofrequency
Description: pulse radiofrequency at 45 V for 300 seconds at 42 degrees Celsius is applied to the posterior tibial nerve area. During the procedure, the temperature at the electrode tip is kept below 42°C. Following negative aspiration (in the absence of blood), 2 cc of 1% lidocaine + 4 mg dexamethasone is applied to the same area.

Intervention type: PROCEDURE
Intervention: plantar fasciitis radiofrequency
Description: the spur area on the calcaneal bone is identified, and sensory and motor stimulations are applied using the RF cannula. If no sensory or motor response is elicited in the area, conventional radiofrequency at 45 V for 60 seconds at 80 degrees Celsius is applied to the spur area after confirming the placement of the RF cannula.

Intervention type: PROCEDURE
Intervention: plantar fasciitis radiofrequency
Description: the spur area on the calcaneal bone is identified, and sensory and motor stimulations are applied using the RF cannula. If no sensory or motor response is elicited in the area, conventional radiofrequency at 45 V for 60 seconds at 80 degrees Celsius is applied to the spur area after confirming the placement of the RF cannula.
Study: NCT06136468

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual coach
Description: The virtual coch will be displayed to the participants using an optical see-through head-mounted display
Study: NCT00662077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronate
Description: Ibandronate endovenous 3 mg every 3 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle modifications
Description: Lifestyle modifications: counseling every 3 months

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle modifications
Description: Lifestyle modifications: counseling every 3 months
Study: NCT05864534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: Balstilimab 450 mg IV over 30 minutes every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: Botensilimab1mg/kg mg IV over 30 minutes every 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Doxorubicin
Description: Liposomal Doxorubicin 30 mg IV over 30 minutes every 3 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sonocloud-9 (SC-9)
Description: Device activation of 9 ultrasound emitters during IV injection of microbubbles every 3 weeks
Study: NCT04753294

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Avance Solo NPWT System
Description: Wound treatment with Avance Solo NPWT System for up to 28 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Avance Solo Adapt NPWT System
Description: Wound treatment with Avance Solo Adapt NPWT System for up to 28 days.
Study: NCT05201846

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIA:CONN G8 insulin pump
Description: Subjects on continuous subcutaneous insulin infusion system with CGM

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multiple daily insulin injection
Description: Subjects on multiple daily insulin injection with CGM
Study: NCT04987112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAN1012
Description: CAN1012 IT injection (once every 4 weeks)
Study: NCT05051046

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy under hypnosis
Description: The hypnosis used will be of the Ericksonian type. Before the colonoscopy begins, the IDE puts the patient in a hypnotic situation.
Study: NCT05465369

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: giomer
Description: injectable flowable Giomer composites is a material used for direct filling techniques has been developed over the past years. It has the property of Giomer technology that able to release and recharge fluoride and other beneficial ions for the life of the restoration and induce remineralization of the underlying hard dental tissues . Injectable flowable Giomer composite (Beautifil flow plus x) has a long-term clinical performance like conventional composite., it also aids in decrease acid production and formation of antiacid resistant layer, help in reduction of tooth mineral solubility also it has high survival rate and wear resistance in high stress bearing areas in posterior teeth Beautifil Flow Plus X also helps to remineralise the tooth structure for sustainable caries prevention and easily polishes for long-lasting luster

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high viscosity glass ionomer
Description: High viscous glass ionomer, the most suitable restorative material for ART procedure and can be used outside the dental clinic, which increases the opportunity for dental care , using a high-viscosity glass-ionomer as an ART sealant in both primary and permanent posterior teeth have a high caries preventive effect High viscosity glass ionomer (EQUIA Fil) has new technology involves ultrafine, and highly reactive glass diffused within the glass-ionomer fillers to increase and enhance matrix formation. This system allows ion availability and builds a stronger matrix structure with greater physical properties, wear resistance and fluoride release. Mechanical properties and fluoride release is the most important features to evaluate glass ionomer restorative material and it's proven that EQUIA Fil fulfilled all these requirement
Study: NCT05362370

Intervention type: DEVICE
Intervention: Stryker's PEEK Customized Implant
Description: The PEEK Customized Implants will be used in this patient cohort for augmentation and/or restoration of bony and/or soft tissue deformities in the cranial and craniofacial skeleton (orbital rim, zygoma, and adjacent bone); including but not limited to, the correction and prevention of persistent temporal hollowing (PTH).
Study: NCT04860479

Intervention type: DEVICE
Intervention: ultrasound
Description: ultrasonography to inguinal region

Intervention type: DEVICE
Intervention: ultrasound
Description: ultrasonography to inguinal region

Intervention type: DEVICE
Intervention: ultrasound
Description: ultrasonography to inguinal region

Intervention type: DEVICE
Intervention: ultrasound
Description: ultrasonography to inguinal region

Intervention type: DEVICE
Intervention: ultrasound
Description: ultrasonography to inguinal region

Intervention type: DEVICE
Intervention: ultrasound
Description: ultrasonography to inguinal region
Study: NCT05262335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib + Oxaliplatin + Capecitabine
Description: 1. Before 6 cycles, Anlotinib 12mg, po.qd, d1-14; Capecitabine 850 mg/m2, po. bid, d1-14; Oxaliplatin 130 mg/m2, iv (D1). The above schemes are repeated every three weeks.~2. After 6 cycles, the regimen is changed to Anlotinib (12mg, po.qd, d1-14)+ Capecitabine (500 mg, po. bid, d1-21). The regimen is repeated every 3 weeks until the disease progresses or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib + Cisplatin + Paclitaxel/ Docetaxel
Description: 1. Anlotinib 12mg, po.qd, d1-14; Cisplatin 60-75mg/m2, iv, d1/d1-d3; Paclitaxel 135mg/m2, iv (D1). or Docetaxel 75mg/m2, iv (D1). The above schemes are repeated every three weeks.~2. After 6 cycles, the regimen is changed to Anlotinib (12mg, po.qd, d1-14)+ Capecitabine (500 mg, po. bid, d1-21). The regimen is repeated every 3 weeks until the disease progresses or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib + Standard first-line chemotherapy
Description: 1. Anlotinib 12mg, po.qd, d1-14; Standard first-line chemotherapy determined by the researchers. The above schemes are repeated every three weeks.~2. After 6 cycles, the regimen is changed to Anlotinib (12mg, po.qd, d1-14)+ Capecitabine (500 mg, po. bid, d1-21). The regimen is repeated every 3 weeks until the disease progresses or unacceptable toxicity.
Study: NCT04613518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Specified Dose on Specified Days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Specified Dose on Specified Days
Study: NCT05157880

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovering Together
Description: In the skills-based intervention group, sessions focus on developing skills to cope and manage ANI related stressors. The intervention will be tailored consistent with AHA recommendations for ANI skills-based interventions and will include 2 general and 4 specific modules. It is anticipated that the intervention will have 6 sessions with 2 general sessions delivered, in person if possible, within the NICU, or through live video using Zoom if patients leave the hospital before sessions occur, and 4 tailored specific sessions (chosen from by the dyads from 6 available modules) to be delivered via live video using Zoom.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Recovering Together
Description: Those in the educational program will receive general health information that mimics the skills-based intervention, but without teaching any of the resiliency or interpersonal communication skills that are hypothesized to be responsible for improvement in emotional distress. There will also be 6 sessions, 2 in-person dyadic visits in the NICU and 4 dyadic virtual visits following discharge. The educational program group will not have the opportunity to specify which modules they would like to take; the modules will be predetermined. All participants will receive medical care as determined by their medical team.
Study: NCT05994547

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Byfavo
Description: For induction and maintenance of sedation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: For induction and maintenance of sedation
Study: NCT05354518

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: gestational diabetes management of midwifery students
Description: Gestational diabetes management of midwifery students with a simulator